Список литературы

40. Stagnaro-Green A., Abalovich M., Alexander E., Azizi F., Mestman J., Negro R., Nixon A., Pearce E.N., Soldin O.P., Sullivan S., Wiersinga W.; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011 Oct; 21(10): 1081–125. doi: 10.1089/thy.2011.0087.

41. Lockwood C.M., Grenache D.G., Gronowski A.M. Serum human chorionic gonadotropin concentrations greater than 400,000 IU/L are invariably associated with suppressed serum thyrotropin concentrations. Thyroid. 2009 Aug; 19(8): 863–8. doi: 10.1089/thy.2009.0079.

42. Abalovich M., Vázquez A., Alcaraz G., Kitaigrodsky A., Szuman G., Calabrese C., Astarita G., Frydman M., Gutiérrez S. Adequate levothyroxine doses for the treatment of hypothyroidism newly discovered during pregnancy. Thyroid. 2013 Nov; 23(11): 1479–83. doi: 10.1089/thy.2013.0024.

43. Castillo Lara M., Vilar Sánchez Á., Cañavate Solano C., Soto Pazos E., Iglesias Álvarez M., González Macías C., Ayala Ortega C., Moreno Corral L.J., Fernández Alba J.J. Hypothyroidism screening during first trimester of pregnancy // BMC Pregnancy Childbirth. 2017 Dec 22; 17(1): 438. doi: 10.1186/s12884-017-1624-x.

44. Li C., Shan Z., Mao J., Wang W., Xie X., Zhou W., Li C., Xu B., Bi L., Meng T., Du J., Zhang S., Gao Z., Zhang X., Yang L., Fan C., Teng W. Assessment of thyroid function during first-trimester pregnancy: what is the rational upper limit of serum TSH during the first trimester in Chinese pregnant women? // J Clin Endocrinol Metab. 2014 Jan; 99(1): 73–9. doi: 10.1210/jc.2013-1674.

45. Casey B.M., Thom E.A., Peaceman A.M., Varner M.W., Sorokin Y., Hirtz D.G., Reddy U.M., Wapner R.J., Thorp J.M. Jr, Saade G., Tita A.T., Rouse D.J., Sibai B., Iams J.D., Mercer B.M., Tolosa J., Caritis S.N., VanDorsten J.P.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal — Fetal Medicine Units Network. Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy // N Engl J Med. 2017 Mar 2; 376(9): 815–825. doi: 10.1056/NEJMoa1606205.

46. Taylor P.N., Muller I., Nana M., Velasco I., Lazarus J.H. Indications for treatment of subclinical hypothyroidism and isolated hypothyroxinaemia in pregnancy. Best Pract Res Clin Endocrinol Metab. 2020 Jul; 34(4): 101436. doi: 10.1016/j.beem.2020.101436.

47. Spencer L., Bubner T., Bain E., Middleton P. Screening and subsequent management for thyroid dysfunction pre-pregnancy and during pregnancy for improving maternal and infant health. Cochrane Database Syst Rev. 2015 Sep 21;(9): CD011263. doi: 10.1002/14651858.CD011263.pub2.

48. Maraka S., Mwangi R., McCoy R.G., Yao X., Sangaralingham L.R., Singh Ospina N.M., O’Keeffe D.T., De Ycaza A.E., Rodriguez-Gutierrez R., Coddington C.C. 3rd, Stan M.N., Brito J.P., Montori V.M. Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment // BMJ. 2017 Jan 25; 356: i6865. doi: 10.1136/bmj.i6865.

49. Rotondi M., Chiovato L., Pacini F., Bartalena L., Vitti P. Management of Subclinical Hypothyroidism in Pregnancy: A Comment from the Italian Society of Endocrinology and the Italian Thyroid Association to the 2017 American Thyroid Association Guidelines — «The Italian Way». Thyroid. 2018 May; 28(5): 551–555. doi: 10.1089/thy.2017.0424.

50. Korevaar T., Medici M., Visser T. et al. Thyroid disease in pregnancy: new insights in diagnosis and clinical management // Nat Rev Endocrinol. 2017; 13: 610–622. https://doi.org/10.1038/nrendo.2017.93.

51. Plowden T.C., Schisterman E.F., Sjaarda L.A., Perkins N.J., Silver R., Radin R., Kim K., Galai N., DeCherney A.H., Mumford S.L. Thyroid-stimulating hormone, anti-thyroid antibodies, and pregnancy outcomes // Am J Obstet Gynecol. 2017 Dec; 217(6): 697.e1–697.e7. doi: 10.1016/j.ajog.2017.09.001.

1. Kars M., Souverein P.C., Herings R.M., Romijn J.A., Vandenbroucke J.P., de Boer A., Dekkers O.M. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia // J Clin Endocrinol Metab. 2009 Aug; 94(8): 2729–34.

2. Freeman M.E., Kanyicska B., Lerant A., Nagy G. Prolactin: structure, function, and regulation of secretion // Physiol Rev. 2000 Oct; 80(4): 1523–631.

3. Grattan D.R. 60 years of neuroendocrinology: The hypothalamo-prolactin axis // J Endocrinol. 2015 Aug; 226(2): T101–22.

4. Handwerger S., Markoff E., Richards R. Regulation of the synthesis and release of decidual prolactin by placental and autocrine/paracrine factors. Placenta. 1991 Mar–Apr; 12(2): 121–30.

5. Kletzky O.A., Marrs R.P., Howard W.F., McCormick W., Mishell D.R. Jr. Prolactin synthesis and release during pregnancy and puerperium // Am J Obstet Gynecol. 1980 Feb 15; 136(4): 545–50.

6. Levin G., Rottenstreich A. Prolactin, prolactin disorders, and dopamine agonists during pregnancy // Hormones (Athens). 2019 Jun; 18(2): 137–139.

7. Gonzalez J.G., Elizondo G., Saldivar D., Nanez H., Todd L.E., Villarreal J.Z. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging // Am J Med. 1988 Aug; 85(2): 217–20.

8. Dinç H., Esen F., Demirci A., Sari A., Resit Gümele H. Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment. Acta Radiol. 1998 Jan; 39(1): 64–9.

9. Elster A.D., Sanders T.G., Vines F.S., Chen M.Y. Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging. Radiology. 1991 Nov; 181(2): 531–5.

10. Scheithauer B.W., Sano T., Kovacs K.T., Young W.F. Jr, Ryan N., Randall R.V. The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases // Mayo Clin Proc. 1990 Apr; 65(4): 461–74.

11. Karaca Z., Tanriverdi F., Unluhizarci K., Kelestimur F. Pregnancy and pituitary disorders // Eur J Endocrinol. 2010 Mar; 162(3): 453–75.

12. Grattan D.R., Steyn F.J., Kokay I.C., Anderson G.M., Bunn S.J. Pregnancy-induced adaptation in the neuroendocrine control of prolactin secretion // J Neuroendocrinol. 2008 Apr; 20(4): 497–507.

13. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М.: Триада, 2004. 304 с.

14. Федеральные клинические рекомендации по гиперпролактинемии: клиника, диагностика, дифференциальная диагностика и методы лечения МЗ РФ. 2015. 19 с.

15. Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A., Wass J.A.; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline // J Clin Endocrinol Metab. 2011 Feb; 96(2): 273–88.

16. Daly A.F., Beckers A. The Epidemiology of Pituitary Adenomas // Endocrinol Metab Clin North Am. 2020 Sep; 49(3): 347–355.

17. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994 Oct 6; 331(14): 904–9.

18. Verhelst J., Abs R., Maiter D., van den Bruel A., Vandeweghe M., Velkeniers B., Mockel J., Lamberigts G., Petrossians P., Coremans P., Mahler C., Stevenaert A., Verlooy J., Raftopoulos C., Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients // J Clin Endocrinol Metab. 1999 Jul; 84(7): 2518–22.

19. Vilar L., Freitas M.C., Naves L.A., Casulari L.A., Azevedo M., Montenegro R. Jr, Barros A.I., Faria M., Nascimento G.C., Lima J.G., Nóbrega L.H., Cruz T.P., Mota A., Ramos A., Violante A., Lamounier Filho A., Gadelha M.R., Czepielewski M.A., Glezer A., Bronstein M.D. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients // J Endocrinol Invest. 2008 May; 31(5): 436–44.

20. Kars M., Dekkers O.M., Pereira A.M., Romijn J.A. Update in prolactinomas. Neth J Med. 2010 Mar; 68(3): 104–12.

21. Molitch M.E. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma // Eur J Endocrinol. 2015 May; 172(5): R205–13.

22. Lebbe M., Hubinont C., Bernard P., Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women // Clin Endocrinol (Oxf). 2010 Aug; 73(2): 236–42.

23. Maiter D. Prolactinoma and pregnancy: From the wish of conception to lactation // Ann Endocrinol (Paris). 2016 Jun; 77(2): 128–34.

24. Glezer A., Bronstein M.D. Prolactinomas, cabergoline, and pregnancy // Endocrine. 2014 Sep; 47(1): 64–9.

25. Crosignani P.G., Mattei A.M., Scarduelli C., Cavioni V., Boracchi P. Is pregnancy the best treatment for hyperprolactinaemia? // Hum Reprod. 1989 Nov; 4(8): 910–2.

26. Jeffcoate W.J., Pound N., Sturrock N.D., Lambourne J. Long-term follow-up of patients with hyperprolactinaemia // Clin Endocrinol (Oxf). 1996 Sep; 45(3): 299–303.